| 循环肿瘤标志物在甲状腺癌临床诊疗中应用的研究进展 |
| |
| 引用本文： | 周政,王佳峰,葛明华. 循环肿瘤标志物在甲状腺癌临床诊疗中应用的研究进展[J]. 中华解剖与临床杂志, 2023, 28(3): 203-208. DOI: 10.3760/cma.j.cn101202-20220715-00213 |
| |
| 作者姓名： | 周政 王佳峰 葛明华 |
| |
| 作者单位： | 1蚌埠医学院研究生院,蚌埠 233030;2浙江省人民医院/杭州医学院附属人民医院头颈外科（耳鼻咽喉-头颈外科中心）,杭州 310014;3浙江省内分泌腺体疾病诊治研究重点实验室,杭州 310014;4浙江省恶性肿瘤临床医学研究中心,杭州310014 |
| |
| 基金项目： | 浙江省医药卫生科学研究基金（2021424557）; 浙江省中医药科技计划（2021ZA008） |
| |
| 摘 要： | 目的 总结循环肿瘤标志物应用于甲状腺癌临床诊疗中的研究进展。方法 在中国知网、万方数据库以及PubMed等中英文数据库中,检索2022年7月之前发表的肿瘤标志物与甲状腺癌临床应用的相关文献共568篇,剔除与内容不符、无法获得全文、重复性研究以及较为陈旧的文献,最终纳入63篇文献进行总结和分析。结果 甲状腺癌是临床最常见的内分泌肿瘤,超声引导下细针穿刺细胞学检查（FNAB）是其诊断的金标准,但存在15%~20%的不准确性。近年来,作为一种新型的非侵入性诊断工具,对包括循环肿瘤细胞（CTCs）、细胞游离DNA（cfDNA）/循环肿瘤DNA（ctDNA）、外泌体以及游离的非编码RNAncRNA）等在内的循环肿瘤标志物的检测,在甲状腺乳头状癌和滤泡状癌患者的临床诊疗中发挥了一定的作用,能够在较早期监测到肿瘤进展或复发,从而帮助临床医生制定个体化的治疗方案。然而,关于循环肿瘤标志物与甲状腺髓样癌以及未分化癌的研究仍旧较少,同时ctDNA与非编码RNA（ncRNA）在甲状腺癌临床诊疗中的作用仍不明确,仍需对其分子机制进一步探讨。结论 循环肿瘤标志物检测具有侵袭性小、副作用少、肿瘤异质性代表性强等优势,在甲状腺癌的临床诊疗中具有广泛的应用前景。
|
| 关 键 词： | 甲状腺肿瘤 肿瘤标志物 循环肿瘤细胞 细胞游离DNA 循环肿瘤DNA 外泌体 非编码RNA |
| 收稿时间： | 2022-07-15 |
Research progress on the application of circulating tumor markers in the clinical diagnosis and treatment of thyroid cancer |
| |
| Zhou Zheng,Wang Jiafeng,Ge Minghua. Research progress on the application of circulating tumor markers in the clinical diagnosis and treatment of thyroid cancer[J]. Chinese Journal of Anatomy and Clinics, 2023, 28(3): 203-208. DOI: 10.3760/cma.j.cn101202-20220715-00213 |
| |
| Authors: | Zhou Zheng Wang Jiafeng Ge Minghua |
| |
| Affiliation: | 1.Graduate School, Bengbu Medical College, ;2.Department of Head and Neck Surgery, Center of Otolaryngology-Head and Neck Surgery, Zhejiang Provincial People's Hospital, Hangzhou 310014, China;3.Zhejiang Provincial Key Laboratory of Diagnosis and Treatment of Endocrine Gland Diseases, Hangzhou 310014, China;4.Clinical Research Center for Cancer of Zhejiang Province, Hangzhou 310014, China |
| |
| Abstract: | Objective To summarize the research progress of circulating tumor markers applied in the clinical diagnosis and treatment of thyroid cancer. Methods A total of 568 articles related to the clinical application of circulating tumor markers and thyroid cancer published before July 2022 were searched in Chinese and English databases, such as CNKI, Wanfang, and PubMed. Sixty-three articles were summarized and analyzed by eliminating the papers that did not accord with the content, papers with unavailable full texts, and duplicates. Results Thyroid cancer is the most common endocrine tumor in clinic. Ultrasound-guided fine needle aspiration biopsy (FNAB) was the gold standard in the diagnosis of thyroid cancer, but the inaccuracy is 15%-20%. Circulating tumor markers included circulating tumor cells (CTCs), cell free DNA (cfDNA) or circulating tumor DNA (ctDNA), exosomes, and free non-coding RNA (ncRNA), etc. In recent years, as a new non-invasive diagnostic tool, the detection of circulating tumor markers has played a certain role in the clinical diagnosis and treatment of patients with papillary thyroid cancer and follicular thyroid cancer. It could detect tumor progression or recurrence at an earlier stage, which facilitates the development of individualized treatment plans. However, studies on the relationship of circulating tumor markers with medullary thyroid cancer and undifferentiated thyroid cancer were few, and the importance of ctDNA and ncRNA in thyroid cancer were still not clear. Thus, it was necessary to further explore the molecular mechanism. Conclusion The detection of circulating tumor markers has less invasiveness, less side effects, and the strong representative heterogeneity of tumors; hence, they have broad prospects in the diagnosis and treatment of thyroid cancer. |
| |
| Keywords: | Thyroid neoplasms Tumor marker Circulating tumor cells Cell free DNA Circulating tumor DNA Exosome Non-coding RNA |
|
| 点击此处可从《中华解剖与临床杂志》浏览原始摘要信息 |
|
点击此处可从《中华解剖与临床杂志》下载全文 |
|
